Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/retro-biosciences.md — the filesystem corpus, unchanged. Not an edit.
10.4 kB
Revision 1
Revision 2
lines 7–13 → 7–136 unchanged lines not shown
categories: ["organizations", "longevity"]categories: ["organizations", "longevity"]tags: ["aging", "autophagy", "reprogramming", "biotech", "protein engineering", "healthspan"]tags: ["aging", "autophagy", "reprogramming", "biotech", "protein engineering", "healthspan"]summary: "A longevity biotechnology company funded by Sam Altman with the stated goal of adding ten years of healthy life, working on autophagy, reprogramming and plasma-inspired therapies."summary: "A longevity biotechnology company funded by Sam Altman with the stated goal of adding ten years of healthy life, working on autophagy, reprogramming and plasma-inspired therapies."updated: "2026-07-27"updated: "2026-10-29"issues: ["The 2025 report of a larger funding round is stated without a citation"]issues: ["The 2025 report of a larger funding round is stated without a citation"]------ lines 26–51 → 26–5112 unchanged lines not shown
}}`````` **Retro Biosciences** is a privately held longevity company founded in 2021 and funded initially with $180 million from Sam Altman, with the stated objective of adding ten years to healthy human lifespan. It runs three programmes — small molecules that enhance [[autophagy]], cellular [[partial-reprogramming|reprogramming]], and therapies derived from the [[parabiosis-and-young-blood|young-plasma]] literature — and is more specific in public than its better-funded peers about programmes, goals and timelines. An early collaboration with OpenAI on protein design has drawn most of the attention to it.**Retro Biosciences** is a privately held longevity company founded in 2021 and funded initially with $180 million from Sam Altman, with the stated objective of adding ten years to healthy human lifespan. It runs three programmes: small molecules that enhance [[autophagy]], cellular [[partial-reprogramming|reprogramming]], and therapies derived from the [[parabiosis-and-young-blood|young-plasma]] literature. In public it is more specific than its better-funded peers about programmes, goals and timelines. Most of the attention it receives has come from an early collaboration with OpenAI on protein design. ## Overview## Overview The company's framing is deliberately narrower than the field's usual rhetoric. Rather than treating aging as a single process to be reversed, it selected three mechanisms with existing preclinical support and organized around getting each into humans. Joe Betts-LaCroix, a hardware engineer turned entrepreneur who previously co-founded a computing company and had been involved in longevity advocacy, is chief executive.The company frames its work more narrowly than the field's usual rhetoric, and does so deliberately. Rather than treating aging as a single process to be reversed, it selected three mechanisms with existing preclinical support and organized itself around getting each into humans. Joe Betts-LaCroix, a hardware engineer turned entrepreneur who previously co-founded a computing company and had been involved in longevity advocacy, is chief executive. Retro is smaller than [[altos-labs]] by an order of magnitude in capital, and its public posture is correspondingly more concrete: it names its programmes, states a numerical goal, and has discussed clinical timelines, none of which its larger competitor does.Retro has an order of magnitude less capital than [[altos-labs]], and its public posture is correspondingly more concrete. It names its programmes, states a numerical goal, and has discussed clinical timelines, none of which its larger competitor does. ## History## History The company was formed in 2021 and operated quietly until March 2023, when MIT Technology Review reported that Sam Altman, then chief executive of OpenAI, had personally invested $180 million — the whole of the company's funding at that point.[^regalado2023] Altman has described the investment as motivated by an interest in extending healthy life rather than by a commercial thesis, and holds no operational role.The company was formed in 2021 and operated quietly until March 2023, when MIT Technology Review reported that Sam Altman, then chief executive of OpenAI, had personally invested $180 million, the whole of the company's funding at that point.[^regalado2023] Altman has described the investment as motivated by an interest in extending healthy life rather than by a commercial thesis, and he holds no operational role. In January 2025 the same publication reported a collaboration between Retro and OpenAI on a model called GPT-4b micro, trained to propose redesigned versions of proteins in the manner described under [[ai-protein-design]].[^regalado2025] The reported application was engineering variants of the [[yamanaka-factors]] — specifically SOX2 and KLF4 — to improve reprogramming efficiency, with Retro claiming a large increase in the expression of markers associated with pluripotency induction. The result was announced through press coverage rather than a peer-reviewed paper, and independent replication has not been published.In January 2025 the same publication reported a collaboration between Retro and OpenAI on a model called GPT-4b micro, trained to propose redesigned versions of proteins in the manner described under [[ai-protein-design]].[^regalado2025] The reported application was engineering variants of two of the [[yamanaka-factors]], SOX2 and KLF4, to improve reprogramming efficiency, and Retro claimed a large increase in the expression of markers associated with pluripotency induction. The result was announced through press coverage rather than a peer-reviewed paper, and independent replication has not been published. ```timeline```timeline[[ { "year": "2021", "title": "Founded", "text": "Retro Biosciences is established in the Bay Area with three programme areas and a stated ten-year healthspan goal." }, { "year": "2021", "title": "Founded", "text": "Retro Biosciences is established in the Bay Area with three programme areas and a stated ten-year healthspan goal." }, { "year": "2023", "title": "Funding disclosed", "text": "MIT Technology Review reports Sam Altman's $180 million personal investment, at the time the company's entire capital." }, { "year": "2023", "title": "Funding disclosed", "text": "MIT Technology Review reports Sam Altman's $180 million personal investment, at the time the company's entire capital." }, { "year": "2025", "title": "Protein design collaboration", "text": "Retro and OpenAI report a purpose-built model proposing improved Yamanaka factor variants, announced via press rather than publication." }, { "year": "2025", "title": "Protein design collaboration", "text": "Retro and OpenAI report a purpose-built model proposing improved Yamanaka factor variants, announced via press rather than publication." }, { "year": "2025–2026", "title": "Toward the clinic", "text": "The company moves its lead autophagy-enhancing compound toward first-in-human testing and reports seeking substantially larger funding." } { "year": "2025-2026", "title": "Toward the clinic", "text": "The company moves its lead autophagy-enhancing compound toward first-in-human testing and reports seeking substantially larger funding." }]]`````` lines 53–72 → 53–721 unchanged line not shown
### Autophagy enhancement### Autophagy enhancement The most developed programme targets autophagy, the lysosomal degradation pathway whose molecular machinery Yoshinori Ohsumi worked out in yeast and for which he received the 2016 Nobel Prize in Physiology or Medicine.[^ohsumi2016] Autophagic flux declines with age in most tissues studied, and genetic or pharmacological enhancement extends lifespan in flies, worms and mice; nearly every intervention that reliably extends lifespan in model organisms, including [[caloric-restriction]] and [[rapamycin]], appears to require an intact autophagy pathway, which is why it recurs across the [[hallmarks-of-aging]] as a shared downstream node. Retro's approach is a small molecule intended to raise flux without the immunosuppression that accompanies mTOR inhibition, with an initial indication in neurodegeneration, where failing [[proteostasis]] is a well-established feature of disease.The most developed programme targets autophagy, the lysosomal degradation pathway whose molecular machinery Yoshinori Ohsumi worked out in yeast and for which he received the 2016 Nobel Prize in Physiology or Medicine.[^ohsumi2016] Autophagic flux declines with age in most tissues studied, and genetic or pharmacological enhancement extends lifespan in flies, worms and mice. Nearly every intervention that reliably extends lifespan in model organisms, including [[caloric-restriction]] and [[rapamycin]], appears to require an intact autophagy pathway, so autophagy recurs across the [[hallmarks-of-aging]] as a shared downstream node. Retro's approach is a small molecule intended to raise flux without the immunosuppression that accompanies mTOR inhibition. Its initial indication is in neurodegeneration, where failing [[proteostasis]] is a well-established feature of disease. The gap between the model-organism evidence and human benefit is wide and the company acknowledges it. No autophagy-enhancing drug has demonstrated a clinical benefit in an aging-related indication in humans.The gap between the model-organism evidence and human benefit is wide, and the company acknowledges it. No autophagy-enhancing drug has demonstrated a clinical benefit in an aging-related indication in humans. ### Cellular reprogramming### Cellular reprogramming The reprogramming programme pursues the same goal as [[altos-labs]] and [[newlimit]]: restoring youthful cell function without loss of cell identity. It differs from both in route. Retro works on the reprogramming factors themselves, engineering variants of the canonical set, which is where the OpenAI collaboration was applied, while NewLimit treats the canonical factors as the wrong tool and screens for combinations that never approach pluripotency. Neither route removes the delivery problem.The reprogramming programme pursues the same goal as [[altos-labs]] and [[newlimit]]: restoring youthful cell function without loss of cell identity. It takes a different route from both. Retro works on the reprogramming factors themselves, engineering variants of the canonical set (the work to which the OpenAI collaboration was applied), while NewLimit treats the canonical factors as the wrong tool and screens for combinations that never approach pluripotency. Neither route removes the delivery problem. ### Plasma-derived therapeutics### Plasma-derived therapeutics The third programme derives from heterochronic parabiosis, in which young and old mice share a circulation and the old animal shows improvements in several tissues. The interpretation of those experiments is contested — whether the effect comes from youthful factors added or from aged factors diluted — and the plasma-transfusion clinics that grew up around them drew a public warning from the US Food and Drug Administration in 2019. Retro's stated approach is to identify specific circulating factors rather than to transfuse plasma, which sidesteps the strongest objection to the commercial versions.The third programme derives from heterochronic parabiosis, in which young and old mice share a circulation and the old animal shows improvements in several tissues. The interpretation of those experiments is contested over whether the effect comes from youthful factors added or from aged factors diluted, and the plasma-transfusion clinics that grew up around them drew a public warning from the US Food and Drug Administration in 2019. Retro's stated approach is to identify specific circulating factors rather than to transfuse plasma, which sidesteps the strongest objection to the commercial versions. > [!caution] Mice, not people> [!caution] Mice, not people> Every mechanism Retro works on rests on rodent evidence. Autophagy enhancement, partial reprogramming and heterochronic blood exchange have all produced functional improvements in mice. None has been shown to extend healthy life in humans, and the company's ten-year target is a goal, not a projection supported by data.> Every mechanism Retro works on rests on rodent evidence. Autophagy enhancement, partial reprogramming and heterochronic blood exchange have all produced functional improvements in mice. None has been shown to extend healthy life in humans, and the company's ten-year target is a goal rather than a projection supported by data. ## Funding and structure## Funding and structure lines 76–90 → 76–903 unchanged lines not shown
## Reception## Reception The scientific reception has been more favourable than that given to most well-publicized longevity ventures, largely because the company works on established mechanisms rather than novel claims and has been explicit about the preclinical state of the evidence. Specialists who are skeptical of the field's rhetoric have noted that autophagy enhancement is a reasonable target with a plausible path to an approvable indication.Scientists have received the company more favourably than most well-publicized longevity ventures, largely because it works on established mechanisms rather than novel claims and has been explicit about the preclinical state of the evidence. Specialists who are skeptical of the field's rhetoric have noted that autophagy enhancement is a reasonable target with a plausible path to an approvable indication. Criticism has focused on three points. The ten-years-of-healthy-life goal has no operational definition; [[healthspan]] is not a standardized measure, no qualified [[aging-biomarkers|surrogate endpoint]] exists, and no trial design has been proposed that would demonstrate the claim within the lifetime of the company. The GPT-4b micro result was communicated through journalism rather than publication, which is the pattern the field has been criticized for since the resveratrol episode associated with [[david-sinclair]]. And a company organized around a specific numerical promise faces an incentive to define success downward, which the absence of a preregistered endpoint makes easy.Criticism has focused on three points. First, the ten-years-of-healthy-life goal has no operational definition: [[healthspan]] is not a standardized measure, no qualified [[aging-biomarkers|surrogate endpoint]] exists, and no trial design has been proposed that would demonstrate the claim within the lifetime of the company. Second, the GPT-4b micro result was communicated through journalism rather than publication, the pattern the field has been criticized for since the resveratrol episode associated with [[david-sinclair]]. Third, a company organized around a specific numerical promise faces an incentive to define success downward, which the absence of a preregistered endpoint makes easy. ## Outlook## Outlook Retro's near-term significance is that it may be first among the well-funded reprogramming and geroprotection companies to generate human data. A phase-one safety result for an autophagy enhancer, followed by a phase-two efficacy signal in a neurodegenerative indication, would be the first time any of this generation of longevity companies has produced evidence a regulator recognizes. A null result would be equally informative, and considerably more likely on base rates for central nervous system drugs.In the near term, Retro may be the first of the well-funded reprogramming and geroprotection companies to generate human data. A phase-one safety result for an autophagy enhancer, followed by a phase-two efficacy signal in a neurodegenerative indication, would be the first time any of this generation of longevity companies has produced evidence a regulator recognizes. A null result would be equally informative, and considerably more likely on base rates for central nervous system drugs. The AI-assisted protein engineering strand is the more consequential unknown. If purpose-trained models can reliably propose transcription-factor variants with improved function, that changes the cost structure of protein engineering across the field, well beyond [[epigenetic-reprogramming]]. The claim as reported is large enough that the absence of a peer-reviewed description more than a year later is itself a data point.The AI-assisted protein engineering strand is the more consequential unknown. If purpose-trained models can reliably propose transcription-factor variants with improved function, that changes the cost structure of protein engineering across the field, well beyond [[epigenetic-reprogramming]]. Given how large the reported claim is, the absence of a peer-reviewed description more than a year later is itself informative. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
89 lines are the same in both revisions, and 37 of them are not shown. Neither revision here is necessarily the current article — read Retro Biosciences for the text this wiki stands behind today.